NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
May 2007
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
NEUPRO (rotigotine) by UCB Pharma is dopamine agonists [moa]. Approved for nonergot dopamine agonist [epc]. First approved in 2007.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEUPRO (rotigotine) is a nonergot dopamine agonist delivered via transdermal extended-release film patch, approved by the FDA on May 9, 2007. It is indicated for the treatment of Parkinson's disease and restless legs syndrome by providing continuous dopaminergic stimulation through skin absorption. The transdermal route of administration offers advantages in patient compliance and steady-state drug delivery compared to oral dopamine agonists. NEUPRO represents an important option in the dopamine agonist class, which is a foundational therapy in early Parkinson's disease management.
$0.1BPart D
5.8 years to LOEMechanism of Action
Dopamine Agonists
Pharmacologic Class:
Nonergot Dopamine Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease
Started Aug 2021
38 enrolled
Parkinson Disease
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
Started Jun 2020
56 enrolled
Parkinson Disease
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
Started Dec 2019
10 enrolled
Restless Legs Syndrome
An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
Started Dec 2019
31 enrolled
Parkinson Disease
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
Started Dec 2018
23 enrolled
Restless Legs Syndrome
Worked on NEUPRO at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.